intranasal orexin positive modulator / Paratek Pharmaceuticals, Centessa - LARVOL DELTA

Sosei Heptares: Significant progress by Orexia and Inexia with orexin agonist program triggers next tranche of funding from Medicxi (PRNewswire) - "Sosei Group Corporation...announces that significant scientific progress at its spin-off companies Orexia Limited ('Orexia') and Inexia Limited ('Inexia') has triggered the next tranche of funding from venture capital firm Medicxi under its €40 million commitment. Sosei Heptares and Medicxi...created Orexia and Inexia in 2019 to develop novel therapies based on positive modulators of the G protein-coupled receptors (GPCRs) Orexin OX1 and OX2 for neurological diseases, including narcolepsy."

Financing

Sosei Heptares announces Medicxi to invest up to €40 million in new collaboration based on its orexin agonist program (PRNewswire) - "Under the terms of the agreement, Orexia and Inexia will obtain a portfolio of related patents from the Company[2] and have the rights to exploit a series of Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, designed and developed by the Company...Specific target indications will be determined as the programs advance, and will include narcolepsy, a rare sleep disorder."

Financing

Newly added product (Labiotech.eu) - Preclinical, Sleep disorder

Pipeline update